Roche’s RG6024 Showing Promise in Huntington’s Disease Study | CheckRare.com

Scott Schobel, MD, MSc, clinical science leader for Roche’s Huntington Disease Program, discusses RG6042, a RNA antisense drug that can reduce the synthesis of the Huntington protein and thereby, reduce its toxic effects in the brain.

Read the full article here

Related Articles